Bank of Japan Officials Signal Continued Interest Rate Hikes Amid Inflation Concerns 
Finnair Orders 18 Embraer E195-E2 Jets in Landmark Fleet Overhaul 
Bank of Japan Unveils New Inflation Gauge to Support Case for Future Rate Hikes 
Australia-EU Free Trade Deal Signed After Years of Negotiations 
OpenAI Pulls the Plug on Sora, Ending $1 Billion Disney Partnership 
9 Tips for Avoiding Tax Season Cyber Scams 
WTO Reform Talks Begin in Cameroon Amid Global Trade Tensions 
Asian Currencies Weaken as Dollar Rebounds Amid Middle East Uncertainty and Japan Inflation Data 
Air Canada Express Crash at LaGuardia: Controller Distracted by Prior Emergency 
Gold is meant to be a ‘safe haven’ in uncertain times. Why is it crashing amid a war? 
Middle East War Rattles Global Markets as Oil Tops $100 and Dollar Surges 
NAB Plans to Cut 170 Jobs While Expanding Offshore Operations 
Reflection AI Eyes $25 Billion Valuation in Massive $2.5 Billion Funding Round 
Time to buy local: war fuel price shocks reveal the folly of a long food supply chain 
Currency Markets Show Caution Amid U.S.-Iran Negotiations 
Wall Street Slides as Iran War Uncertainty, Oil Surge, and AI Fears Rattle Markets 
Rio Tinto's Resolution Copper Mine: U.S. Smelting Challenges and Global Operations Update 
Merck & Co Inc. gets the green light from the Japanese health ministry for its COVID-19 anti-viral pill. The health officials recommended the approval of the said medicine late last week.
The approval of the Merck coronavirus pill is said to be part of the country’s Prime Minister Fumio Kishida’s plan to introduce and distribute new treatments by the end of the year as the growing cases of Omicron variant infection is becoming a very serious concern.
According to Inquirer.net, the committee’s decision has led to the shipments of around 200,000 doses starting this weekend. This is just the preparation and start of the deliveries as per the announcement of the country’s prime minister.
“I am convinced the distribution of this drug is a major step forward for our nation’s COVID–19 handling,” Shigeyuki Goto, Japan’s health minister, told the press after the announcement of the panel’s approval of Merck’s COVID-19 treatment pill.
He added that some of the country’s pharmacies and medical institutions are expected to begin receiving the medicine as early as next Monday. Moreover, it was said that Japan is really laying bets on oral treatments to prevent cases of severe infections and deaths should a sixth wave of the pandemic arise.
Based on the report, Japan agreed to pay $1.2 billion to Merck and its partner Ridgeback Biotherapeutics for the shipment of 1.6 million courses of molnupiravir. PM Kishida also said last week, the government signed a deal for two million doses of another anti-viral treatment pill and this was developed by Pfizer.
In the U.S., health regulators also authorized the use of the Merck pill for some high-risk adult patients. Many countries are now rushing to purchase the said Merck’s molnupiravir due to promising results during trials.
“As a single oral medicine that can be taken at home, early treatment with molnupiravir significantly reduced the risk of hospitalization or death in patients at high risk for progressing to severe COVID-19,” Merck research laboratories president, Dr. Dean Y. Li, said in a press release. “Importantly for patients, there were markedly fewer deaths among those taking molnupiravir in our clinical study and we believe that it will be a critical addition to the measures available to help curb the impact of COVID-19 on patients, healthcare systems, and public health in Japan.”
